Regulation, competition and prices in health product markets;Regulación, competencia y precios en los mercados de productos sanitarios

Gaceta Sanitaria

Volumn 20, Issue SUPPL. 2, 2006, Pages 3-13

  Gonzalez Lopez Valcarcel, Beatriz ^a   Domínguez, Jaime Pinilla ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

European Union; Health policy; Healthcare economics and organizations; Medical devices

Indexed keywords

EID: 34547676006     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1157/13089478     Document Type: Review

References (33)

1. Pammolli F, Riccaboni M, Oglialoro C, Magazzini L, Baio G, Salerno N. Medical devices competitiveness and impact on public health expenditure. 2005. Study prepared for the Directorate Enterprise of the European Commission.
2. Weitzman JB. Electronic medical devices -A primer for pathologists. Arch Pathol Lab Med. 2003;127:814-25.
3. Altenstetter C. Bridging European and member state implementation. The case of medical goods, in vitro diagnostics and equipment. En: Steffen M, editor. Health Governance in Europe. Issues, challenges and theories. Londres: Routledge; 2005. p. 80-112.
4. Altenstetter C. International Collaboration on Medical Device Regulation: Issues, Problems and Stakeholders. En: Mackintosh M, Koivusalo M, editors. Commercialization of Health Care: Global and Local Dynamics and Policy Responses. London: Palgrave; 2005. p. 170-86.
5. Cardiogenesis Corporation; 2005. Disponible en http://phx.corporate-ir. net/phoenix.zhtml?c=116437&p=irol-news
6. Eucomed IATF. The use of Foreign Average Pricing for Medical Devices Marketed in Japan [position paper]. 2005.
7. McNeil K, Minihan E. Regulation of medical devices and organizational behavior in hospitals. Adm Sci Q. 1977;22:475-86.
8. Maisel WH. Medical Device Regulation: An Introduction for the Practicing Physician. Ann Intern Med. 2004;140:296-302.
9. Disponible en: http://europa.eu.int/comm/enterprise/medical_devices/ca/ list_ca.htm
10. Altenstetter C. EU and member state medical devices regulation. Int J Technol Assess Health Care. 2003;19:228-48.
11. Riehmann M. Regulatory measures for implementing new medical devices. Recalling Boneloc®. Dan Med Bull. 2005;52:11-7.
12. Malenka DJ, Kaplan AV, Sharp SM, Wennberg JE. Post-marketing surveillance of medical devices using Medicare claims. Health Aff. 2005;24:928-37.
13. Fereres J, Cano J: Encuesta sobre reutilización de material de un solo uso. El Autoclave, mayo de 2002;52-3.
14. London A, Kadane J. Placebos that harm: sham surgery controls in clinical trials. Stat Methods Med Res. 2002;11:413-27.
15. Albin R. Sham surgery controls: Intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgrery controls. J Med Ethics. 2000;28:322-5.
16. Tenery R, Rakatansky H, Riddick F, Goldrich M, Morse L, O'-Bannon J, et al. Surgical 'placebo' controls. Ann Surg 2002;235:303-7.
17. Barsky A, Saintfort R, Rogers M, Borus J. Nonspecific madication side effects and the nocebo phenomenon. JAMA. 2002; 287.
18. Vickers A. Placebo controls in randomized trials of acupuncture. Eval Health Prof. 2002;25:421-35.
19. Cobb LA, Thomas GI, Dillard GH, Merendino RA, Bruce RA. An evaluation of internal mammary artery ligation by a double blind technic. N Eng J Med. 1959;260:115-8.
20. Dimond EG, Kittle CF, Crockett JE. Comparison of internal mammary artery ligation and sham operation for angina pectoris. Am J Cardiol. 1960;5:483-6.
21. Heckerling PS. Ethical aspects in trials of implantable medical devices. JAMA. 2003;290:1579.
22. a ed. Barcelona: Masson; 2005.
23. González López-Valcárcel B. Difusión de nuevas tecnologías sanitarias y políticas públicas. Barcelona: Masson; 2005.
24. Al-Khatib SM, Lucas FL, Jollis JG, Malenka DJ, Wennberg DE. The Relation Between Patients' Outcomes and the Volume of Cardioverter-Defibrillator Implantation Procedures Performed by Physicians Treating Medicare Beneficiaries. J Am Coll Cardiol. 2005;46:1536-40.
25. Eurostar Data Registry Centre. Progress Report. Endografts in current use only (Ancure, AneuRx, Fortron, Excluder, Lifepath, Talent & Zenith), 2005.
26. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-52.
27. Milewa T, Barry C. Health Policy and the Politics of Evidence. Soc Policy Admin. 2005;39:498-512.
28. Gillick MR. Medicare coverage for technological innovations. Time for new criteria? N Engl J Med. 2004;350:2199-203.
29. a ed. Frankfurt: COCIR; 2003.
30. FENIN FEdEdTS. Libro Blanco I+D+I en el Sector de Productos Sanitarios. 2001. Ministerio de Ciencia y Tecnología y Ministerio de Sanidad y Consumo.
31. Boada Gordon A. Evaluación de los procedimientos de compra públicos del sistema sanitario español en el entorno de la prestación ortoprotésica de acuerdo a los criterios de los agentes implicados. Aplicación de la metodología. Valencia: Universitat de Valencia Servei de Publicacions; 2004.
32. Disponible en: http://www.boe.es/boe/dias/2004-07-21/pdfs/B06463-06463. pdf
33. ECRI [comunicación en Internet]; 2005. Disponible en: www.ecri.org